Morphotek, Inc, a subsidiary of Eisai Corporation of North America, and Pivotal BioSciences, Inc, a privately held Los Angeles-based biotechnology company developing oncology products, have entered into an agreement in which Morphotek will access Pivotal BioSciences' LEC platform technology, developed by Dr Alan Epstein, for the development of therapeutic monoclonal antibodies.
The detailc can be read here.
No comments:
Post a Comment